Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma
Open Access
- 16 October 2023
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 38 (1) , 160-167
Abstract
The primary analysis of the GHSG HD16 trial indicated a significant loss of tumor control with PET-guided omission of radiotherapy (RT) in patients with early-stage favorable Hodgkin lymphoma (HL). This analysis reports long-term outcomes. Overall, 1150 patients aged 18–75 years with newly diagnosed early-stage favorable HL were randomized between standard combined-modality treatment (CMT) (2x ABVD followed by PET/CT [PET-2] and 20 Gy involved-field RT) and PET-2-guided treatment omitting RT in case of PET-2 negativity (Deauville score [DS] < 3). The study aimed at excluding inferiority of PET-2-guided treatment and assessing the prognostic impact of PET-2 in patients receiving CMT. At a median follow-up of 64 months, PET-2-negative patients had a 5-year progression-free survival (PFS) of 94.2% after CMT (n = 328) and 86.7% after ABVD alone (n = 300; HR = 2.05 [1.20–3.51]; p = 0.0072). 5-year OS was 98.3% and 98.8%, respectively (p = 0.14); 4/12 documented deaths were caused by second primary malignancies and only one by HL. Among patients assigned to CMT, 5-year PFS was better in PET-2-negative (n = 353; 94.0%) than in PET-2-positive patients (n = 340; 90.3%; p = 0.012). The difference was more pronounced when using DS4 as cut-off (DS 1-3: n = 571; 94.0% vs. DS ≥ 4: n = 122; 83.6%; p < 0.0001). Taken together, CMT should be considered standard treatment for early-stage favorable HL irrespective of the PET-2-result.Keywords
Funding Information
- Sanofi-Genzyme, Takeda
- Employment/leadership position (University Hospital of Cologne, Head of the GHSG Trial Coordination Centre), honorarium
- Takeda Medical Research Foundation
- Bristol-Myers Squibb Company | Bristol-Myers Squibb Canada
- BeiGene, MSD Stemline
- Gilead Sciences
- Miltenyi Biotec
- Novartis
- Roche
- Amgen
- Pfizer
- Merck & Co., Inc. | Merck Sharp and Dohme
- AbbVie
- AstraZeneca
- allogene, Cerus, incyte, IQVIA, Noscendo, Pentixapharm,
This publication has 26 references indexed in Scilit:
- Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's LymphomaJournal of Clinical Oncology, 2010
- Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's LymphomaNew England Journal of Medicine, 2010
- Report on the First International Workshop on interim-PET scan in lymphomaLeukemia & Lymphoma, 2009
- Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelinesRadiotherapy and Oncology, 2006
- Combined-Modality Therapy Versus Radiotherapy Alone for Treatment of Early-Stage Hodgkin's Disease: Cure Balanced Against ComplicationsJournal of Clinical Oncology, 2006
- Don't Throw Out the Baby With the Bathwater: On Optimizing Cure and Reducing Toxicity in Hodgkin's LymphomaJournal of Clinical Oncology, 2006
- State-of-the-Art Therapeutics: Hodgkin's LymphomaJournal of Clinical Oncology, 2005
- Randomized Comparison of ABVD Chemotherapy With a Strategy That Includes Radiation Therapy in Patients With Limited-Stage Hodgkin’s Lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2005
- Chemotherapy Alone for Early Hodgkin's Lymphoma: An Emerging OptionJournal of Clinical Oncology, 2005
- High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's diseaseAnnals of Hematology, 1993